- Published on
Toxicology – Thyroid Products
Core Concept
Thyroid-hormone poisoning results from excessive exposure to levothyroxine (T4), liothyronine (T3), desiccated thyroid preparations containing both T4 and T3, or combination products.
The characteristic toxicologic sequence is:
Exogenous thyroid hormone → excess intracellular T3 activity → increased metabolic rate + increased adrenergic responsiveness → tachycardia + tremor + agitation + hyperthermia + GI hypermotility ± dysrhythmia/heart failure/seizure
The most important clinical feature is that toxicity—particularly after levothyroxine (T4)—may be delayed for several days after ingestion. A patient can therefore appear completely well shortly after a massive ingestion and subsequently develop thyrotoxicosis.
Most isolated acute levothyroxine ingestions, especially in young children, produce little or no serious toxicity. A 2026 systematic review incorporating more than 11,000 patients found that more than 90% had minimal or no symptoms, although severe complications and rare deaths do occur, particularly in adults with deliberate large ingestions.
Current Thyroid Products
The most important current product is levothyroxine (T4), available under multiple generic and branded formulations. Contemporary full replacement dosing in otherwise healthy adults is approximately 1.6 μg/kg/day, with lower starting doses in older patients or those with cardiovascular disease.
Liothyronine (T3; Cytomel) remains available in 5-, 25-, and 50-μg tablets. Current adult treatment generally starts around 25 μg once daily, with lower doses such as 5 μg/day in older patients or those with cardiovascular disease.
Desiccated porcine thyroid preparations such as Armour Thyroid contain both T4 and T3. One grain, approximately 60–65 mg depending on product convention, provides roughly 38 μg T4 and 9 μg T3 in current Armour Thyroid labeling.
Historical fixed-ratio liotrix (T4/T3) products such as Thyrolar and Euthroid are listed in the FDA’s 2026 discontinued drug product list and are no longer routine contemporary products.
T4 Versus T3 – Critical Toxicologic Difference
Levothyroxine is T4, which functions largely as a circulating prohormone. Approximately 80% of circulating T3 is produced through peripheral deiodination of T4.
Liothyronine is T3, the hormone responsible for most direct thyroid-receptor activity. Current pharmacokinetic data describe T3 as approximately four times as biologically potent as T4 on a microgram basis. T3 is also absorbed rapidly, with onset of pharmacologic activity within hours.
Thus:
T3 poisoning tends to act faster.
T4 poisoning may be delayed because T4 must distribute and undergo conversion to T3.
This difference is especially important when assessing desiccated thyroid or mixed T4/T3 preparations, which can produce both relatively early and delayed manifestations.
Pharmacokinetics
T4 is highly protein bound—approximately 99.96% in current labeling—and has a normal biologic half-life of approximately 6–7 days in euthyroid patients.
T3 is slightly less protein bound, has a biologic half-life of approximately 2–2.5 days, and reaches tissues more rapidly.
Thyroid hormones undergo hepatic metabolism, conjugation, biliary excretion, and enterohepatic recirculation, which provides the rationale for using bile-acid sequestrants such as cholestyramine in substantial poisoning.
Pathophysiology
T3 and T4 enter cells and ultimately influence nuclear thyroid-hormone receptors, altering gene transcription and protein synthesis.
Excess thyroid-hormone action increases:
Basal metabolic rate → oxygen consumption → heat production
Carbohydrate/lipid/protein turnover → catabolic state
Cardiac adrenergic responsiveness → tachycardia + increased contractility + dysrhythmia
GI motility → diarrhea + abdominal symptoms
CNS excitability → tremor + anxiety + agitation ± seizures
Current liothyronine labeling emphasizes that thyroid-hormone effects are mediated through nuclear receptor control of DNA transcription and protein synthesis.
Thyroid Hormone Does Not Simply “Increase Catecholamine Levels”
The older description that toxicity results primarily from increased catecholamine concentrations is overly simplistic.
A major clinical effect of thyroid hormone is increased tissue responsiveness to adrenergic stimulation, including increased β-adrenergic activity. This explains why beta-blockade can rapidly improve tachycardia, tremor, hypertension, and anxiety even though it does not immediately remove thyroid hormone.
Toxic Dose
There is no reliable single toxic dose of levothyroxine.
Endotext notes that one-time ingestion of up to approximately 3 mg of levothyroxine often causes little or no toxicity, particularly in children, but this should not be treated as a safety threshold.
Serious toxicity has been reported after substantially smaller ingestions than historical “massive-dose” thresholds. For example, a child developed a generalized seizure after a maximum possible ingestion of 3.6 mg levothyroxine.
More importantly, both historical and modern series demonstrate poor correlation between reported dose, serum thyroid-hormone concentration, and clinical severity. A 2015 poison-center study found late symptoms after acute overdose and no clear dose distinction between symptomatic and asymptomatic groups.
Therefore:
Treat the patient and the clinical trajectory—not the reported milligram dose alone.
Why Acute Levothyroxine Overdose Is Often Surprisingly Mild
Several mechanisms limit immediate toxicity.
T4 is highly protein bound, requires conversion to T3 for much of its biologic activity, distributes gradually into tissues, and exerts many effects through changes in gene transcription rather than direct receptor-channel activation.
Young children also appear remarkably tolerant of even relatively large single ingestions.
The 2026 systematic review of levothyroxine overdose found that severe outcomes were uncommon despite reported ingestions frequently involving several milligrams.
Chronic Toxicity Is Different
Repeated supratherapeutic administration can produce much more clinically important thyrotoxicosis than a single acute ingestion because tissues have had time to accumulate hormone and develop the full physiologic effects of excess T3.
Chronic excess may result from:
Prescription error + deliberate weight-loss misuse + factitious thyrotoxicosis + accidental repeated dosing + formulation error
Patients may present with established tachyarrhythmia, weight loss, tremor, hyperthermia, psychiatric symptoms, heart failure, or osteoporosis rather than a recognizable “overdose.”
Risk Factors for Severe Toxicity
Older adults and patients with underlying cardiovascular disease are particularly susceptible.
Important risk factors include:
Coronary artery disease, atrial fibrillation, heart failure, structural heart disease, advanced age, large T3 exposure, chronic overuse, and significant coingestants.
Current liothyronine labeling specifically emphasizes the increased risk of atrial arrhythmias and cardiovascular adverse effects in elderly patients.
Clinical Onset – Levothyroxine
Levothyroxine toxicity can be delayed for days.
Current levothyroxine labeling explicitly states that symptoms may not appear until several days after ingestion.
Endotext reports that manifestations after massive T4 ingestion may be delayed as long as approximately 3–10 days, although milder symptoms commonly appear earlier.
Pediatric case reports document clinically significant thyrotoxicosis developing 24 hours to 4 days after an initially asymptomatic presentation.
Therefore:
A normal examination in the first few hours does not exclude later levothyroxine toxicity.
Clinical Onset – Liothyronine
T3 acts substantially faster.
Current labeling describes onset of liothyronine activity within a few hours, with maximum pharmacologic response within approximately 2–3 days.
Thus, isolated T3 overdose or a mixed T3/T4 preparation may become symptomatic earlier than pure levothyroxine exposure.
Clinical Features
The typical syndrome is a hypermetabolic, hyperadrenergic state characterized by:
Tachycardia + tremor + anxiety/agitation + diaphoresis + heat intolerance + diarrhea
More severe poisoning can produce atrial fibrillation, severe hypertension or hypotension, heart failure, myocardial ischemia, hyperthermia, delirium, psychosis, seizures, coma, and thyroid storm-like multiorgan failure. Current levothyroxine and liothyronine labels recognize seizures, shock, coma, and death as possible manifestations of major overdose.
Vital Signs
Common abnormalities include:
Sinus tachycardia, systolic hypertension, tachypnea, and fever.
Severe toxicity may progress to hypotension because of dehydration, tachyarrhythmia, cardiomyopathy, or cardiovascular collapse.
Cardiovascular Toxicity
Cardiovascular manifestations are the principal concern in adults.
They include:
Sinus tachycardia, palpitations, atrial fibrillation, supraventricular tachycardia, ventricular ectopy, hypertension, angina, myocardial ischemia, heart failure, and rarely shock.
Older adults and those with underlying coronary or structural cardiac disease are at greatest risk.
Current Cytomel labeling specifically notes that atrial fibrillation is the most frequently observed arrhythmia with excessive thyroid-hormone exposure in older patients.
Gastrointestinal Effects
Thyroid-hormone excess increases gastrointestinal motility.
Patients may develop:
Nausea, vomiting, abdominal discomfort, diarrhea, and increased appetite.
Fluid losses can produce dehydration and worsen tachycardia.
Neurologic and Psychiatric Effects
Manifestations include:
Anxiety, restlessness, irritability, insomnia, tremor, headache, hyperreflexia, agitation, confusion, psychosis, and delirium.
Seizures and coma are rare but recognized severe complications.
In a pediatric case, a seizure developed on the third day after acute levothyroxine ingestion, illustrating the possibility of delayed serious neurologic toxicity.
Hyperthermia
Increased metabolic heat production can cause fever or hyperthermia.
Severe hyperthermia suggests major thyrotoxicosis or thyroid storm and can contribute to:
Rhabdomyolysis + dehydration + renal injury + CNS dysfunction
Cooling and treatment of the underlying thyrotoxicosis are essential.
Musculoskeletal Effects
Weakness and tremor are common.
Prolonged severe hyperthermia, agitation, or seizures can occasionally produce rhabdomyolysis.
CK should be checked when clinically indicated.
Thyroid Storm
True thyroid storm from exogenous thyroid-hormone overdose is rare, but a severe overdose can create a storm-like syndrome with:
Hyperthermia + marked tachycardia/atrial fibrillation + CNS dysfunction + GI/hepatic abnormalities + heart failure
Thyroid storm is a clinical diagnosis rather than simply an extreme T4 or T3 level. Current Endotext guidance emphasizes fever, marked tachycardia, heart failure, tremor, sweating, GI symptoms, agitation/psychosis, delirium/coma, and jaundice among the typical manifestations.
A patient with storm physiology requires ICU management.
Important Difference – Exogenous Overdose Versus Endogenous Thyroid Storm
Standard thyroid-storm algorithms were largely designed for endogenous hormone overproduction, such as Graves disease.
In pure levothyroxine or liothyronine overdose:
The problem is hormone already swallowed—not excessive synthesis by the thyroid gland.
Therefore drugs that block new thyroid-hormone synthesis, such as methimazole, have little mechanistic value in a pure exogenous overdose.
Iodine likewise primarily blocks endogenous thyroid-hormone release and is unlikely to help when thyrotoxicosis is caused by exogenous hormone ingestion. A 2026 consensus statement specifically notes that iodine is unlikely to be beneficial in factitious/exogenous thyrotoxicosis because circulating hormone is coming from outside the gland rather than ongoing synthesis.
Diagnosis
Diagnosis is based on:
Exposure history + clinical findings + thyroid-function testing
The most characteristic laboratory pattern is:
Elevated free/total T4 and/or T3 + suppressed TSH
depending on the product and timing.
Endotext documents elevated total and free T4/T3 with suppressed TSH after levothyroxine overdose.
TSH
TSH is useful for confirming thyroid-hormone excess but is not an acute toxicity marker.
Suppression may lag behind the exposure, especially very early after an acute ingestion.
Do not use a normal early TSH to exclude overdose.
Free T4 and T3
Obtain free T4 and T3 when a significant ingestion is suspected.
The pattern can provide important clues:
Pure levothyroxine ingestion → marked T4 elevation followed by increasing T3 from conversion
Liothyronine ingestion → disproportionate T3 elevation
Desiccated thyroid/mixed preparation → elevation of both
However:
Hormone concentration correlates imperfectly with clinical severity.
Endotext notes that delayed symptoms do not correlate closely with plasma T4 and T3 concentrations.
Serial Thyroid Hormone Levels
Serial free T4/T3 testing is useful after a major ingestion, particularly when the patient is symptomatic or the concentration is still rising.
T4 and T3 can continue increasing during the first 24 hours after ingestion because absorption continues.
Laboratory trends can help demonstrate that the exposure is resolving, but treatment should remain primarily clinical.
Thyroglobulin
A low or suppressed thyroglobulin supports chronic exogenous/factitious thyrotoxicosis because endogenous thyroid secretion is suppressed.
It is usually not required for the emergency management of an obvious acute tablet ingestion but can be useful when the source of thyrotoxicosis is uncertain.
ECG
Obtain an ECG in symptomatic patients, substantial deliberate ingestions, older adults, or anyone with cardiovascular disease.
Continuous cardiac monitoring is appropriate for:
Persistent tachycardia, atrial fibrillation, chest pain, heart failure, hypotension, significant hyperthermia, or severe thyrotoxicosis.
Additional Laboratory Evaluation
In moderate or severe toxicity, obtain:
Electrolytes, glucose, renal function, liver function, CK, and other studies dictated by the presentation.
Troponin is appropriate for chest pain or suspected myocardial ischemia.
Blood gas and lactate may be useful in shock, severe hyperthermia, seizures, or multiorgan toxicity.
Differential Diagnosis
Important toxicologic mimics include:
Sympathomimetics, caffeine/theophylline, anticholinergic poisoning, serotonin syndrome, salicylates, MAOI toxicity, drug withdrawal, and other causes of adrenergic excess.
Nontoxicologic causes include:
Endogenous hyperthyroidism, pheochromocytoma, sepsis, hypoglycemia, panic/agitation syndromes, and other hypermetabolic states.
Initial Treatment
Most acute isolated levothyroxine exposures require primarily:
Observation + supportive care
For a meaningful symptomatic exposure:
Stop thyroid hormone → monitor vital signs/ECG → control adrenergic symptoms → manage temperature/fluids → consider cholestyramine and glucocorticoid in substantial toxicity
A poison center or medical toxicologist should be involved after a large intentional ingestion, T3-containing ingestion, significant symptoms, or high-risk cardiovascular exposure.
Gastrointestinal Decontamination – Ipecac
Do not induce vomiting.
The old recommendation to use ipecac after thyroid-hormone overdose is obsolete.
Induced emesis has no established modern role in poisoning management.
Gastric Lavage
The routine gastric-lavage recommendations in older thyroid-product chapters and some legacy drug labels should not be followed.
AACT/EAPCCT guidance states that gastric lavage should not be performed routinely, if at all, because outcome benefit has not been demonstrated and serious complications can occur.
Therefore:
Routine gastric lavage is obsolete after thyroid-hormone ingestion.
Activated Charcoal
A single dose of activated charcoal may be considered after a recent substantial ingestion when the patient presents early and has an intact or protected airway.
General toxicology evidence indicates that benefit is greatest during approximately the first hour, although some potential benefit may persist later in selected circumstances.
It should not be administered routinely after trivial exposures.
Multiple-Dose Activated Charcoal
Multiple-dose activated charcoal is not an established enhanced-elimination therapy for levothyroxine.
Endotext notes that repeated charcoal has generally not effectively accelerated levothyroxine elimination, despite occasional historical use.
AACT/EAPCCT guidance reserves true MDAC enhanced-elimination therapy mainly for a small group of poisons such as carbamazepine, dapsone, phenobarbital, quinine, and theophylline—not thyroid hormone.
Beta-Blockers
Beta-blockers are the most immediately useful drugs for clinically important adrenergic symptoms.
They control:
Tachycardia + tremor + palpitations + hypertension + anxiety
Propranolol additionally reduces peripheral conversion of T4 → T3 at sufficiently high doses, making it particularly attractive after levothyroxine overdose.
Endotext lists propranolol among the main therapies for significant thyroxine poisoning.
Propranolol
For a stable symptomatic adult, oral propranolol can be titrated according to heart rate and blood pressure.
Historical overdose regimens commonly used approximately:
Propranolol 10–40 mg orally every 6–8 hours
with individualized titration.
More aggressive thyroid-storm dosing is higher, but should not automatically be applied to an otherwise stable overdose patient.
Beta-Blocker Caution
Do not give large fixed beta-blocker doses blindly to a patient with decompensated heart failure or low-output shock.
Beta-blockade can precipitate cardiovascular collapse in severe thyrotoxicosis when tachycardia is maintaining cardiac output.
Current 2025–2026 thyroid-storm guidance recommends cautious initial beta-blocker dosing and favors a rapidly titratable agent such as esmolol when cardiac function is uncertain.
Esmolol
For severe tachycardia in an ICU patient, particularly when hemodynamic tolerance is uncertain, esmolol is attractive because of its short half-life.
Current Endotext thyroid-storm guidance describes an IV loading dose around 250–500 μg/kg, followed by approximately 50–100 μg/kg/min, titrated cautiously.
In exogenous overdose, dosing should be individualized rather than automatically treating every tachycardic patient as thyroid storm.
Reactive Airway Disease
When nonselective beta-blockade poses unacceptable bronchospasm risk, a short-acting or β₁-selective strategy may be considered.
Current thyroid-storm guidance recognizes agents such as metoprolol or atenolol when reactive airway disease limits propranolol use.
Cholestyramine
Cholestyramine binds thyroid hormone in the gastrointestinal tract and interrupts enterohepatic recycling, increasing fecal elimination.
A commonly used adult regimen in significant poisoning is:
Cholestyramine 4 g orally every 6–8 hours
Endotext specifically lists 4 g every 8 hours for thyroxine poisoning, while thyroid-storm regimens may use up to four times daily.
This is most useful in substantial symptomatic poisoning or prolonged thyrotoxicosis rather than minor accidental exposure.
Glucocorticoids
Glucocorticoids inhibit peripheral conversion of:
T4 → T3
and therefore have a rational role in severe levothyroxine poisoning or thyroid storm-like toxicity.
Endotext describes dexamethasone as a treatment option for major thyroxine overdose, while modern storm therapy commonly uses hydrocortisone or dexamethasone.
A common severe-thyrotoxicosis regimen is:
Dexamethasone 2 mg IV/PO every 6 hours
or
Hydrocortisone approximately 100 mg IV every 8 hours
with dosing individualized to the clinical syndrome.
Propylthiouracil – Major Modern Nuance
PTU has two actions:
Inhibits new thyroid-hormone synthesis
and
Reduces peripheral T4 → T3 conversion
The second mechanism provides some theoretical benefit in levothyroxine poisoning.
However:
PTU does not remove the huge quantity of exogenous T4 already swallowed.
Endotext therefore characterizes PTU as having very limited usefulness in massive levothyroxine exposure.
For most isolated exogenous overdoses, propranolol, supportive care, cholestyramine, and glucocorticoid therapy are more mechanistically useful.
Methimazole
Methimazole inhibits new thyroid-hormone synthesis but does not meaningfully block peripheral T4-to-T3 conversion.
Therefore:
Methimazole generally has little role in a pure levothyroxine or liothyronine overdose.
It is appropriate when severe thyrotoxicosis is actually being driven by an endogenous hyperthyroid gland rather than exogenous tablets.
Iodine
Iodine suppresses thyroid-hormone release from the thyroid gland.
That is useful in endogenous thyroid storm caused by Graves disease or toxic nodular disease.
It is not useful for hormone already present in the circulation after tablet ingestion.
A recent consensus statement specifically emphasizes that iodine therapy is unlikely to benefit factitious/exogenous thyrotoxicosis.
Therefore:
Do not reflexively give iodine for pure exogenous thyroid-hormone poisoning.
Sodium Ipodate and Iopanoic Acid
Older texts recommended iodinated contrast drugs such as sodium ipodate to block T4-to-T3 conversion.
These drugs are no longer generally available, making these historical regimens largely obsolete. Endotext explicitly notes that sodium ipodate is no longer generally available.
Hyperthermia Treatment
Use:
External cooling + IV fluids as needed + treatment of agitation and thyrotoxicosis
Acetaminophen can be used for fever, although much of the temperature elevation is caused by increased metabolic heat production rather than a hypothalamic prostaglandin set-point.
Avoid aspirin in severe thyrotoxicosis/thyroid storm.
Salicylates can displace thyroid hormone from binding proteins and transiently increase free thyroid-hormone concentrations. Current thyroid-storm guidance recommends acetaminophen instead.
Dantrolene
The older text mentions successful use of dantrolene.
Dantrolene is not routine treatment for thyroid-hormone poisoning or thyroid storm.
Modern management centers on cooling, beta-blockade, supportive care, glucocorticoids, and hormone-directed therapies rather than dantrolene.
Seizures
Treat seizures with:
Benzodiazepines first-line
followed by standard toxicologic status-epilepticus management when necessary.
The older routine suggestion of phenytoin should not supersede modern benzodiazepine-based seizure management.
Simultaneously correct hyperthermia, hypoxia, metabolic abnormalities, and severe thyrotoxicosis.
Dysrhythmias
Most uncomplicated sinus tachycardia responds to beta-blockade and supportive care.
Atrial fibrillation should be managed according to hemodynamics and the severity of thyrotoxicosis.
Unstable tachydysrhythmias require standard cardioversion/resuscitation.
The key treatment remains correction of the thyroid-hormone-driven hyperadrenergic state.
Heart Failure and Cardiogenic Shock
Severe thyrotoxicosis can produce high-output heart failure, tachycardia-mediated cardiomyopathy, or occasionally low-output cardiogenic shock.
Bedside echocardiography is valuable when severe heart failure or hypotension is present before aggressive beta-blockade.
Recent thyroid-storm consensus guidance emphasizes that beta-blockade can precipitate collapse when severe systolic dysfunction is present and recommends short-acting esmolol when blockade is necessary but hemodynamic tolerance is uncertain.
Thyroid Storm From Exogenous Hormone
If an overdose produces true thyroid-storm physiology, treatment should focus on the components that actually affect exogenous hormone:
ICU supportive care
Beta-blockade when hemodynamically safe
Glucocorticoid to reduce T4 → T3 conversion
Cholestyramine to enhance elimination
Thionamides and iodine should not automatically be included because they principally target thyroid-gland synthesis and release, which may already be suppressed in pure exogenous poisoning.
Plasmapheresis / Therapeutic Plasma Exchange
Thyroid hormones are highly protein bound, so therapeutic plasma exchange (TPE) can physically remove hormone together with binding proteins.
TPE is not required for ordinary thyroid-hormone overdose.
It may be considered when there is:
Severe refractory thyroid storm + cardiovascular collapse + progressive multiorgan failure despite maximal conventional treatment
Modern 2025–2026 thyroid-storm guidance recognizes plasmapheresis as an established rescue option for refractory cases.
Hemoperfusion
Charcoal hemoperfusion has been reported to lower T4 concentrations in severe poisoning.
However, evidence consists largely of case reports, and modern availability is limited.
It should be regarded as an exceptional rescue technique, not routine therapy.
Hemodialysis
Ordinary hemodialysis is poorly effective at removing thyroid hormone.
T4 is approximately 99.96% protein bound, severely limiting dialyzability.
Endotext similarly considers hemodialysis of limited value in levothyroxine poisoning.
Dialysis should therefore not be initiated simply to clear T4.
It remains appropriate for an independent renal or metabolic indication.
Exchange Transfusion
Exchange transfusion has occasionally been described in severe thyroid-hormone poisoning, particularly historically.
It is not standard contemporary treatment and should be regarded as an exceptional rescue option when conventional therapy and more practical extracorporeal methods are unavailable or ineffective.
No Specific Antidote
There is no specific antidote that directly neutralizes circulating T3 or T4.
Treatment works by:
Blocking adrenergic manifestations
Reducing T4 → T3 conversion
Reducing intestinal absorption/reabsorption
Providing supportive critical care
and, exceptionally, physically removing protein-bound hormone with plasma exchange.
Pediatric Poisoning
Accidental levothyroxine ingestion in young children is common relative to adult overdose and is usually surprisingly benign.
In a 2026 multicenter pediatric study, only about one-third of children became symptomatic, with tachycardia being the most common manifestation.
Historical pediatric series similarly found mostly minor symptoms and poor correlation between dose or hormone concentration and clinical effects.
Nevertheless, rare seizures, delayed thyrotoxicosis, and major cardiovascular abnormalities have been documented.
Do Not Use a Rigid Pediatric “Toxic Dose”
Published thresholds such as 0.1 mg/kg, 1.5 mg, or 3 mg should not be interpreted as absolute boundaries between safe and toxic exposure.
Severe events have occasionally occurred at doses below older thresholds, while much larger ingestions have produced very little toxicity.
Poison-center risk assessment is therefore more useful than a fixed milligram cutoff.
Pregnancy
The historical FDA Pregnancy Category A system is obsolete.
Levothyroxine is not only safe when correctly prescribed during pregnancy—it is essential treatment for maternal hypothyroidism.
Current labeling states that decades of clinical experience have not demonstrated increased rates of major malformations, miscarriage, or other adverse fetal outcomes from therapeutic levothyroxine exposure, and therapy should not be discontinued during pregnancy. Pregnancy often increases the replacement dose required.
Liothyronine labeling similarly reports no increased rate of major birth defects or miscarriage from therapeutic exposure.
These reassuring therapeutic data do not mean a massive overdose is harmless. Severe maternal hyperthermia, dysrhythmia, cardiovascular collapse, or thyroid storm threatens both mother and fetus and should be treated aggressively.
Breastfeeding
Therapeutic levothyroxine is compatible with breastfeeding.
Current labeling reports that levothyroxine is present in human milk but that adverse effects in breastfed infants have not been reported.
Liothyronine is also present in milk, although published infant-outcome data are more limited.
Therapeutic lactation data should not automatically be extrapolated to a mother after a major acute overdose.
Monitoring After Acute Levothyroxine Overdose
The patient should be monitored primarily for clinical evidence of thyrotoxicosis, not simply until the laboratory values normalize.
For substantial exposures, useful follow-up includes:
Heart rate + blood pressure + temperature + mental status + ECG when indicated + serial free T4/T3
Because delayed toxicity is well documented, patients and caregivers must receive explicit instructions regarding delayed symptoms even after an initially reassuring evaluation.
Observation Period
The older approach of simply discharging every asymptomatic patient after immediate gastrointestinal decontamination is too simplistic.
There is no universally validated fixed observation period because levothyroxine effects may appear days later.
Most minor accidental pediatric ingestions can still be managed conservatively after poison-center assessment, because serious toxicity is rare.
However, prolonged observation/admission should be considered with:
Large intentional ingestion, T3-containing product, symptoms, significant cardiovascular disease, older age, abnormal ECG, substantial coingestion, or unreliable follow-up.
Delayed Outpatient Follow-Up
Because symptoms can emerge after discharge, patients or caregivers should be advised to return urgently for:
Persistent tachycardia, palpitations, fever, tremor, severe agitation, confusion, chest pain, dyspnea, vomiting/diarrhea with dehydration, or seizure.
Follow-up for several days is particularly important after a large T4 ingestion.
Admission
Hospital admission is appropriate for:
Persistent significant tachycardia, hypertension requiring therapy, significant hyperthermia, dysrhythmia, chest pain, heart failure, marked agitation, neurologic symptoms, seizure, substantial T3 exposure, or evolving thyroid storm.
Older adults and patients with major cardiovascular disease deserve a lower admission threshold.
ICU Admission
ICU management is warranted for:
Thyroid storm, severe hyperthermia, atrial or ventricular dysrhythmia with instability, myocardial ischemia, heart failure/cardiogenic shock, seizure, coma, or multiorgan dysfunction.
Discharge
The historical rule that hospital discharge should wait until the T3 concentration is below 350–400 ng/dL should not be used as a universal modern criterion.
Hormone levels correlate poorly with clinical toxicity.
Discharge should instead be based on:
Clinical stability + controlled heart rate + normal mental status + absence of important dysrhythmia + improving trajectory + safe delayed follow-up.
Prognosis
The prognosis after acute isolated levothyroxine ingestion is generally excellent.
A 2026 systematic review found mortality to be extremely rare even after large ingestions, with the majority of patients experiencing minimal or no symptoms.
The major exceptions are patients with severe intentional overdose, chronic overexposure, substantial T3 exposure, advanced age, or significant cardiovascular disease.
Important Pitfalls
The first major pitfall is assuming that the patient is safe because the first few hours are uneventful.
Levothyroxine toxicity can be delayed for several days.
Current labeling explicitly warns that manifestations may not appear until days after ingestion.
Another pitfall is assuming that an extremely high T4 concentration automatically predicts severe toxicity.
Serum T4/T3 concentrations correlate poorly with clinical severity.
A clinically well child can have extraordinary hormone levels, while a susceptible older adult may develop major cardiovascular toxicity at a much lower concentration.
Another important distinction is:
T3 is not simply “stronger T4.”
Liothyronine acts within hours and has direct biologic activity, whereas levothyroxine has slower kinetics and undergoes substantial conversion to T3.
Do not automatically treat pure exogenous overdose with the complete Graves-disease thyroid-storm regimen.
Methimazole and iodine do little to remove thyroid hormone that has already been swallowed.
Their mechanisms target endogenous synthesis/release.
PTU has some theoretical usefulness because it reduces T4-to-T3 conversion, but even Endotext describes its value after massive exogenous T4 loading as limited.
Sodium ipodate is historical and is no longer generally available.
Do not induce vomiting, and do not perform routine gastric lavage.
Modern toxicology guidance states that lavage should not be used routinely, if at all.
Activated charcoal is selective rather than mandatory, with greatest potential benefit after a recent substantial ingestion and a protected airway.
Do not routinely use multiple-dose charcoal to enhance levothyroxine elimination. Evidence suggests that it does not reliably accelerate elimination.
Do not give large propranolol doses blindly to a patient with possible thyrotoxic cardiomyopathy.
Beta-blockade can precipitate cardiovascular collapse in severe low-output heart failure.
Use cautious dosing and consider short-acting esmolol when ventricular function is uncertain.
Do not use aspirin to treat severe thyrotoxic hyperthermia because salicylates may increase the free thyroid-hormone fraction. Acetaminophen and physical cooling are preferred.
Do not expect hemodialysis to remove clinically meaningful quantities of T4.
T4 is approximately 99.96% protein bound.
The historical FDA pregnancy-category system is obsolete. Therapeutic levothyroxine should continue during pregnancy, and pregnancy often requires a higher replacement dose.
High-Yield Toxicology Pearls
Thyroid-hormone overdose = delayed hypermetabolic/adrenergic toxicity.
The main products are:
Levothyroxine = T4
Liothyronine = T3
Desiccated thyroid = T4 + T3
Historical liotrix products such as Thyrolar/Euthroid are now on the FDA discontinued-product list.
T3 is approximately four times as potent per microgram as T4 and acts within hours. Most circulating T3 normally arises through conversion from T4.
The classic clinical syndrome is:
Tachycardia + tremor + anxiety/agitation + diaphoresis + fever + diarrhea
Severe toxicity can cause:
Atrial fibrillation + myocardial ischemia/heart failure + hyperthermia + psychosis + seizures + thyroid storm
Levothyroxine symptoms may be delayed for several days.
An initially asymptomatic patient is not necessarily past the risk period.
Most acute pediatric levothyroxine ingestions are benign, and more than 90% of patients in contemporary pooled data develop minimal or no symptoms. Severe complications remain possible but are rare.
There is no reliable toxic-dose threshold.
One-time ingestions up to about 3 mg frequently cause little toxicity, yet seizures and major symptoms have occasionally occurred at doses in that range.
Serum testing usually shows:
↑ free T4/T3 + ↓ TSH
but laboratory magnitude does not reliably predict severity.
For symptomatic thyrotoxicosis:
Beta-blocker therapy is usually the most immediately useful treatment.
Propranolol controls adrenergic symptoms and also decreases peripheral T4 → T3 conversion.
Use caution in decompensated heart failure; short-acting esmolol is preferable when hemodynamic tolerance is uncertain.
For significant levothyroxine toxicity:
Cholestyramine 4 g PO every 6–8 hours
can enhance thyroid-hormone elimination by interrupting intestinal recycling.
Glucocorticoids reduce peripheral T4 → T3 conversion and are appropriate in severe toxicity or thyroid storm-like presentations.
Methimazole and iodine are generally not useful for pure exogenous thyroid-hormone overdose.
They suppress endogenous synthesis/release rather than neutralizing tablets that have already been absorbed.
PTU can reduce T4-to-T3 conversion but has only a limited role after a large exogenous T4 load.
Sodium ipodate is historical and is no longer generally available.
Do not induce vomiting. Routine gastric lavage is obsolete. A single dose of activated charcoal can be considered early after a meaningful ingestion when airway safety is assured.
Multiple-dose charcoal is not routinely useful for levothyroxine elimination.
Hemodialysis has limited efficacy because thyroid hormone is extremely protein bound.
Therapeutic plasma exchange is a specialist rescue therapy for rare severe refractory cases.
Therapeutic levothyroxine is safe and necessary during pregnancy and is compatible with breastfeeding. The old Pregnancy Category A terminology should no longer be used.
The single most important clinical warning is:
After a large levothyroxine ingestion, “asymptomatic now” does not mean “safe later”—T4 toxicity may not declare itself for several days.